Elixinol to Acquire 25 Percent Stake in US-Based CBD Pet Products Brand Pet Releaf
April 25th, 2019
DENVER, April 24, 2019 (GLOBE NEWSWIRE) — Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, today announced that they have purchased a 25 percent stake in Altmeds LLC, maker of the pioneering and market leading Pet Releaf hemp-derived CBD pet line. Pet Releaf sales accounted for approximately 65 percent of the market’s pet CBD sales last year.
Pet Releaf hemp-derived CBD topical, edibles and oils for pets currently sell in over 4,000 independent pet stores throughout the USA and multiple international markets. By acquiring a stake in Pet Releaf, Elixinol will strengthen its relationship with a major private label partner and secure a profitable investment in the fast-growing hemp-derived CBD pet products market, while ensuring Pet Releaf has the financial resources to innovate, expand and scale.
“Pet Releaf and Elixinol share the same values in sourcing and end-product superiority,” said Stephen Smith, President and Co-Founder of Pet Releaf. “The partnership of two best-in-class companies means Pet Releaf will gain additional working capital to be able to expand our reputation for innovation, and increase our scientific and international expertise while still maintaining our ‘from seed to sale from plant to pet™’ approach.”
Elixinol is the exclusive supplier of final hemp extract sourced from the USDA Organic certified hemp strain grown specifically for Pet Releaf. The founders of Pet Releaf and Elixinol have shared scientific, farming and production ideas, expertise and strategy for many years. Since inception, Pet Releaf has been a foundational customer of Elixinol with both organizations starting in Colorado in 2014. Together, the two strong brands leverage seed to sale supply chain efficiencies with extensive scalability, in-house scientific expertise and proprietary processing technologies.
Pet Releaf will use the majority of the investment to fund working capital and scale the business for expected continued growth in the market, through new product lines, key strategic hires and increased capacity in a new state of the art 25,000 square-foot production facility.
The move gives Elixinol greater exposure to the lucrative and growing CBD pet products market. According to recent research by cannabis market research firm, Brightfield Group, this market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 151% between 2018-2022 to a market size of US$1.16bn.
Upon completion of Elixinol gaining an equity interest, Elixinol’s President Gabriel Ettenson will join the Pet Releaf Board. Ettenson stated, “We’ve long enjoyed our relationship with Pet Releaf. This deal strengthens our supply arrangements and mutual and synergistic distribution networks. It ensures Pet Releaf products, which so many dog and cat lovers rely on, will have scalability and ongoing quality of supply.”
“Pets play an important role in the lives of many Elixinol customers,” added Chris Husong, VP of marketing and communications at Elixinol. “Pet Releaf products give pet owners peace of mind by using the same quality CBD hemp in their pet treats as Elixinol uses in our human products. We’re excited to strengthen the relationship with trusted pet products brand and partner, Pet Releaf.”
Colorado-based Elixinol, co-founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and extracting high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. Elixinol distributes CBD products in 40 countries globally including North and South America, throughout Europe, Asia, and the Pacific Region. Elixinol’s parent company, EXL (elixinolglobal.com) is publicly traded on the Australian Securities Exchange and the US-based OTCQX (ASX: EXL; OTCQX:ELLXF). More information available at Elixinol.com.
About Pet Releaf™:
Pet Releaf™ is an employee-owned business based in Denver, Colo. The company was co-founded by Alina and Steve Smith in 2015 to provide truly healthy products for pet companions – products that will always be made with honesty and integrity. Spurred by their own dog Mattie’s arthritis and reaction to opioid medications, Alina and Steve embarked on creating their own truly healthy products, which led to the launch of Edibites™ Treats for Dogs and Organic CBD Hemp Oil bottles for dogs and cats. Pet Releaf’s organic, all-natural products are made in small batches, tested by third-party laboratories and do not contain any ingredients sourced from China. For more information about Pet Releaf, please visit www.petreleaf.com or connect with us on Facebook, Twitter,Pinterest, and Instagram.
+1 844-804-3504 ext 420
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.